论文部分内容阅读
目的:以脑得生的有效部位组方,比较脑得生有效部位方与脑得生原方中葛根素在兔体内的生物利用度。方法:分别提取脑得生的有效部位,并以有效部位配伍组方。将实验大白兔分成2组,分别灌胃脑得生的有效部位和脑得生粗提物,采用高效液相色谱法测定不同时间兔血浆中葛根素浓度,应用PKSolver2.0软件计算药动学参数。结果:脑得生有效部位与脑得生粗提物的主要药动学参数:AUC0-4分别为(6.0±3.1)mg.h.L-1和(5.7±3.4)mg.h.L-1,Cmax分别为(3.1±0.9)mg.L-1和(2.87±0.10)mg.L-1,tmax分别为(0.72±0.20)h和(0.73±0.10)h,两者无明显差异,相对生物利用度为(106.7±10.0)%。结论:脑得生由其有效部位组方,口饲后,其活性成分的吸收和消除并未发生变化,表现出与脑得生粗提物相同的作用。
OBJECTIVE: To study the bioavailability of puerarin in the brain of the effective part of the brain and the brain of the effective part of the brain. Methods: The effective parts of the brain were extracted, and the effective part of the compatibility group. The experimental rabbits were divided into two groups, respectively, gavage effective part of the brain and crude brain crude extract, using high performance liquid chromatography determination of puerarin concentrations in plasma at different times, using PKSolver2.0 software to calculate pharmacokinetics parameter. Results: The main pharmacokinetic parameters of brain derived active fractions and crude brain extracts were AUC0-4 (6.0 ± 3.1) mg.hL-1 and (5.7 ± 3.4) mg.hL-1, respectively (3.1 ± 0.9) mg.L-1 and (2.87 ± 0.10) mg.L-1, tmax were (0.72 ± 0.20) h and (0.73 ± 0.10) h, respectively, with no significant difference between the two groups. The relative bioavailability (106.7 ± 10.0)%. CONCLUSION: After the brain is born, its absorption and elimination of the active ingredient has not changed after its oral administration. It shows the same effect as crude brain extract.